Biocon’s CANMab (Trastuzumab injection)
CANMab is the world’s first biosimilar (developed in an organism) version of Roche’s Herceptin drug
Bangalore based Bio-technology company Biocon launched a cheaper drug to treat ‘metastatic’ breast cancer
Biocon developed the drug in association with US generic drugmaker Mylan under a global partnership
The drug will be manufactured at its biologics facility in Bangalore
Biocon Ltd : Chairperson and Managing Director – Kiran Mazumdar-Shaw